Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Credit Suisse’s Walton believes that though the market is undoubtedly changing, it will take a lot to shift the advantages of incumbency....
...Jo Walton, an analyst at Credit Suisse, said it was too soon to conclude any significant differences in efficacy between the Covid-19 vaccines — and certainly too early to have any market implications....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Jo Walton, an analyst at Credit Suisse, said the incumbents had reaped the benefits as “amazingly large businesses with apparently high barriers to entry....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Jo Walton, analyst at Credit-Suisse, argued the JV with Novartis may have been “a complicating factor” in GSK’s decision....
...This latter target was set by Mr Soriot during the group’s successful battle to resist a £69.4bn takeover by Pfizer last year....
...“Pfizer has been an exemplar of the fact that scale in its own right adds nothing,” says Jo Walton, head of pharmaceuticals research at Credit Suisse....
...Jo Walton, pharmaceutical analyst with Credit Suisse, also highlights the poor returns on all the money spent by industry in recent years....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“Mega-mergers sought to leverage existing infrastructure by putting new products through it,” says Jo Walton, an analyst with Credit Suisse....
...Fintan Walton, head of PharmaVentures, a life sciences advisory firm, says: “The industry has this huge dilemma over innovation. Acquisitions are part of solving it....
...Iran ready to cut Europe’s oil at once - Facebook to file IPO listing details next week - RBS Chairman Sir Philip Hampton turned down £1.4m bonus before Stephen Hester was awarded £1m - Pfizer...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Greece debt restructuring - Inflation fears resurface on rising clothes prices - George Osborne tax will push up household bills - UK new car sales fall for tenth month in April - Pfizer...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Fintan Walton, head of consultancy PharmaVentures, said: “If it’s a live deal, it’s a bad deal. It doesn’t overcome the patent losses, and a merger will lock them into dormancy for a year....
...Rivals such as Pfizer and AstraZeneca have since followed suit. A third contribution raised by Mr Garnier is the creation of a new corporate culture....
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...says Fintan Walton of Pharma-Ventures, a consultancy. ?They are out there to land-grab the sector by taking out biotech.?...
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition